Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

(MedPage Today) — CHICAGO — Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115728

Author :

Publish date : 2025-05-22 21:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

Mismatch Between Alzheimer’s Biomarkers and Symptoms May Signal Multiple Pathologies

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

Related Posts

‘My son could so easily have been another Nottingham killer’

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

Study Links GLP-1 Drugs to Lower Cancer Risk

FDA Chief Defends Job Cuts, COVID Booster Policy at Senate Hearing

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

‘My son could so easily have been another Nottingham killer’

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

Study Links GLP-1 Drugs to Lower Cancer Risk

FDA Chief Defends Job Cuts, COVID Booster Policy at Senate Hearing

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

AI Assistance May Boost Accuracy of HER2-Low Scoring for Breast Cancers

Survival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast Cancer

Categories

Archives